MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 529403 | Name: Pleconaril
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pleconaril is an antiviral drug potentially for the treatment of enterovirus infection and asthma. Pleconaril, administered either orally or intranasally, is active against viruses in the Picornaviridae family, including Enterovirus and Rhinovirus. Pleconaril has shown useful activity against the dangerous strain enterovirus D68. Pleconaril binds to a hydrophobic pocket in the VP1 protein. Pleconaril has been shown in viral assembly to associate with viral particles.

Chemical Structure

Pleconaril
Pleconaril
CAS#153168-05-9

Theoretical Analysis

MedKoo Cat#: 529403

Name: Pleconaril

CAS#: 153168-05-9

Chemical Formula: C18H18F3N3O3

Exact Mass: 381.1300

Molecular Weight: 381.36

Elemental Analysis: C, 56.69; H, 4.76; F, 14.95; N, 11.02; O, 12.59

Price and Availability

Size Price Availability Quantity
50mg USD 250.00 2 Weeks
100mg USD 450.00 2 Weeks
200mg USD 850.00 2 Weeks
500mg USD 1,650.00 2 Weeks
1g USD 2,450.00 2 Weeks
2g USD 3,850.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
SR-263843; SR-63843; VP-63843; Win-63843; SR263843; SR63843; VP63843; Win63843; SR 263843; SR 63843; VP 63843; Win 63843; Pleconaril, Picovir.
IUPAC/Chemical Name
3-(3,5-dimethyl-4-(3-(3-methylisoxazol-5-yl)propoxy)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole
InChi Key
KQOXLKOJHVFTRN-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H18F3N3O3/c1-10-7-13(16-22-17(27-24-16)18(19,20)21)8-11(2)15(10)25-6-4-5-14-9-12(3)23-26-14/h7-9H,4-6H2,1-3H3
SMILES Code
FC(C1=NC(C2=CC(C)=C(OCCCC3=CC(C)=NO3)C(C)=C2)=NO1)(F)F
Appearance
White to biege solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Pleconaril is a capsid inhibitor used previously to treat enterovirus infections.
In vitro activity:
TBD
In vivo activity:
TBD
Solvent mg/mL mM comments
Solubility
DMF 25.0 65.56
DMSO 65.3 171.32
Ethanol 10.0 26.22
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 381.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
TBD
In vitro protocol:
TBD
In vivo protocol:
TBD
1: Benschop KS, Wildenbeest JG, Koen G, Minnaar RP, van Hemert FJ, Westerhuis BM, Pajkrt D, van den Broek PJ, Vossen AC, Wolthers KC. Genetic and antigenic structural characterization for resistance of echovirus 11 to pleconaril in an immunocompromised patient. J Gen Virol. 2015 Mar;96(Pt 3):571-9. doi: 10.1099/vir.0.069773-0. PubMed PMID: 25395595. 2: Bernard A, Lacroix C, Cabiddu MG, Neyts J, Leyssen P, Pompei R. Exploration of the anti-enterovirus activity of a series of pleconaril/pirodavir-like compounds. Antivir Chem Chemother. 2015 Apr;24(2):56-61. doi: 10.1177/2040206615589035. PubMed PMID: 26071135. 3: Hussain Basha S, Prasad RN. In-Silico screening of Pleconaril and its novel substituted derivatives with Neuraminidase of H1N1 Influenza strain. BMC Res Notes. 2012 Feb 17;5:105. doi: 10.1186/1756-0500-5-105. PubMed PMID: 22340192; PubMed Central PMCID: PMC3369820. 4: Wildenbeest JG, van den Broek PJ, Benschop KS, Koen G, Wierenga PC, Vossen AC, Kuijpers TW, Wolthers KC. Pleconaril revisited: clinical course of chronic enteroviral meningoencephalitis after treatment correlates with in vitro susceptibility. Antivir Ther. 2012;17(3):459-66. doi: 10.3851/IMP1936. PubMed PMID: 22293148. 5: Abzug MJ, Michaels MG, Wald E, Jacobs RF, Romero JR, Sánchez PJ, Wilson G, Krogstad P, Storch GA, Lawrence R, Shelton M, Palmer A, Robinson J, Dennehy P, Sood SK, Cloud G, Jester P, Acosta EP, Whitley R, Kimberlin D; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group.. A Randomized, Double-Blind, Placebo-Controlled Trial of Pleconaril for the Treatment of Neonates With Enterovirus Sepsis. J Pediatric Infect Dis Soc. 2016 Mar;5(1):53-62. doi: 10.1093/jpids/piv015. PubMed PMID: 26407253; PubMed Central PMCID: PMC4765488. 6: Zhang G, Zhou F, Gu B, Ding C, Feng D, Xie F, Wang J, Zhang C, Cao Q, Deng Y, Hu W, Yao K. In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection. Arch Virol. 2012 Apr;157(4):669-79. doi: 10.1007/s00705-011-1222-6. PubMed PMID: 22245989. 7: Schmidtke M, Wutzler P, Zieger R, Riabova OB, Makarov VA. New pleconaril and [(biphenyloxy)propyl]isoxazole derivatives with substitutions in the central ring exhibit antiviral activity against pleconaril-resistant coxsackievirus B3. Antiviral Res. 2009 Jan;81(1):56-63. doi: 10.1016/j.antiviral.2008.09.002. PubMed PMID: 18840470. 8: Lacroix C, Laconi S, Angius F, Coluccia A, Silvestri R, Pompei R, Neyts J, Leyssen P. In vitro characterisation of a pleconaril/pirodavir-like compound with potent activity against rhinoviruses. Virol J. 2015 Jul 14;12:106. doi: 10.1186/s12985-015-0330-4. PubMed PMID: 26169596; PubMed Central PMCID: PMC4501209. 9: Schmidtke M, Hammerschmidt E, Schüler S, Zell R, Birch-Hirschfeld E, Makarov VA, Riabova OB, Wutzler P. Susceptibility of coxsackievirus B3 laboratory strains and clinical isolates to the capsid function inhibitor pleconaril: antiviral studies with virus chimeras demonstrate the crucial role of amino acid 1092 in treatment. J Antimicrob Chemother. 2005 Oct;56(4):648-56. PubMed PMID: 16150864. 10: Ma JD, Nafziger AN, Rhodes G, Liu S, Bertino JS Jr. Duration of pleconaril effect on cytochrome P450 3A activity in healthy adults using the oral biomarker midazolam. Drug Metab Dispos. 2006 May;34(5):783-5. PubMed PMID: 16467135. 11: Hernández M. [A randomized, double-blind, placebo-controlled trial of pleconaril for the treatment of neonates with enterovirus sepsis]. Rev Chilena Infectol. 2016 Jun;33(3):359. doi: 10.4067/S0716-10182016000300021. Spanish. PubMed PMID: 27598292. 12: Ma JD, Nafziger AN, Rhodes G, Liu S, Gartung AM, Bertino JS Jr. The effect of oral pleconaril on hepatic cytochrome P450 3A activity in healthy adults using intravenous midazolam as a probe. J Clin Pharmacol. 2006 Jan;46(1):103-8. PubMed PMID: 16397289. 13: Ledford RM, Collett MS, Pevear DC. Insights into the genetic basis for natural phenotypic resistance of human rhinoviruses to pleconaril. Antiviral Res. 2005 Dec;68(3):135-8. PubMed PMID: 16199099. 14: Pevear DC, Hayden FG, Demenczuk TM, Barone LR, McKinlay MA, Collett MS. Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses. Antimicrob Agents Chemother. 2005 Nov;49(11):4492-9. PubMed PMID: 16251287; PubMed Central PMCID: PMC1280128. 15: Hayden FG, Herrington DT, Coats TL, Kim K, Cooper EC, Villano SA, Liu S, Hudson S, Pevear DC, Collett M, McKinlay M; Pleconaril Respiratory Infection Study Group.. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin Infect Dis. 2003 Jun 15;36(12):1523-32. PubMed PMID: 12802751. 16: Desmond RA, Accortt NA, Talley L, Villano SA, Soong SJ, Whitley RJ. Enteroviral meningitis: natural history and outcome of pleconaril therapy. Antimicrob Agents Chemother. 2006 Jul;50(7):2409-14. PubMed PMID: 16801419; PubMed Central PMCID: PMC1489762. 17: Abzug MJ, Cloud G, Bradley J, Sánchez PJ, Romero J, Powell D, Lepow M, Mani C, Capparelli EV, Blount S, Lakeman F, Whitley RJ, Kimberlin DW; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group.. Double blind placebo-controlled trial of pleconaril in infants with enterovirus meningitis. Pediatr Infect Dis J. 2003 Apr;22(4):335-41. PubMed PMID: 12690273. 18: van de Ven AA, Douma JW, Rademaker C, van Loon AM, Wensing AM, Boelens JJ, Sanders EA, van Montfrans JM. Pleconaril-resistant chronic parechovirus-associated enteropathy in agammaglobulinaemia. Antivir Ther. 2011;16(4):611-4. doi: 10.3851/IMP1792. PubMed PMID: 21685550. 19: Hayden FG, Coats T, Kim K, Hassman HA, Blatter MM, Zhang B, Liu S. Oral pleconaril treatment of picornavirus-associated viral respiratory illness in adults: efficacy and tolerability in phase II clinical trials. Antivir Ther. 2002 Mar;7(1):53-65. PubMed PMID: 12008788. 20: Utzig N, Friedrich B, Burtzlaff C, Lauffer H. [Polio-like myelitis due to Coxsackie-Virus B 3: Course under treatment with pleconaril]. Klin Padiatr. 2003 Sep-Oct;215(5):286-7. German. PubMed PMID: 14520593.